GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Advagene Biopharma Co Ltd (ROCO:6709) » Definitions » Equity-to-Asset

Advagene Biopharma Co (ROCO:6709) Equity-to-Asset : 0.91 (As of Jun. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Advagene Biopharma Co Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Advagene Biopharma Co's Total Stockholders Equity for the quarter that ended in Jun. 2023 was NT$85.13 Mil. Advagene Biopharma Co's Total Assets for the quarter that ended in Jun. 2023 was NT$93.90 Mil.

The historical rank and industry rank for Advagene Biopharma Co's Equity-to-Asset or its related term are showing as below:

ROCO:6709' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.94   Med: 0.95   Max: 0.97
Current: 0.95

During the past 8 years, the highest Equity to Asset Ratio of Advagene Biopharma Co was 0.97. The lowest was 0.94. And the median was 0.95.

ROCO:6709's Equity-to-Asset is ranked better than
94.68% of 1559 companies
in the Biotechnology industry
Industry Median: 0.67 vs ROCO:6709: 0.95

Advagene Biopharma Co Equity-to-Asset Historical Data

The historical data trend for Advagene Biopharma Co's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advagene Biopharma Co Equity-to-Asset Chart

Advagene Biopharma Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial 0.97 0.95 0.96 0.94 0.95

Advagene Biopharma Co Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.96 0.96 0.94 0.91 0.95

Competitive Comparison of Advagene Biopharma Co's Equity-to-Asset

For the Biotechnology subindustry, Advagene Biopharma Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Advagene Biopharma Co's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Advagene Biopharma Co's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Advagene Biopharma Co's Equity-to-Asset falls into.



Advagene Biopharma Co Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Advagene Biopharma Co's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=139.962/147.934
=

Advagene Biopharma Co's Equity to Asset Ratio for the quarter that ended in Jun. 2023 is calculated as

Equity to Asset (Q: Jun. 2023 )=Total Stockholders Equity/Total Assets
=85.133/93.904
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Advagene Biopharma Co  (ROCO:6709) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Advagene Biopharma Co Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Advagene Biopharma Co's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Advagene Biopharma Co (ROCO:6709) Business Description

Traded in Other Exchanges
N/A
Address
Sector 1, Neihu Road, 6 Floor, No.308, Neihu District, Taipei, TWN, 114
Advagene Biopharma Co Ltd is a Taiwan based immune-modulatory platform-based drug developer. The company has completed technology transfer with DCB for detoxified LT Adjuvant Technology Platform. Its product development includes nasal spray influenza vaccine (LT-Flu), allergy vaccines (LT-Allergy), and other vaccines.

Advagene Biopharma Co (ROCO:6709) Headlines

No Headlines